BioMaje helps innovative biotechnology laboratories to perfect, develop and/or optimize their bioproduction tools. Through field experiences in operational, technical, pharmaceutical, and agile project coordination, BioMaje supports you in developing innovative anti-infectious approaches, particularly in the field of pharmabiotics (microbiota and bacteriophages).
In the perspective of having variable-geometry tools with affordable manufacturing costs, bioproduction
is undergoing radical change. Health systems can no longer afford overpriced treatments. Just as
bioproduction has shifted from stainless steel reactors to disposable plastic systems and, in the
future, to recyclable systems, the production of biological drugs must tend towards reducing
BioMaje helps you design and deploy agile and frugal methods and processes to manufacture small batch for a personalized medicine approach, up to millions of treatments commercial batch. The processes must be thought out as early as possible to reach an acceptable production cost; they must be designed to facilitate the transition to industrial production according to Good Manufacturing Practices (GMP), Pharmacopoeias and / or monographs. Quality control tests must be developed early to ensure quality, reproducibility, and campaigns traceability.
BioMaje experts were among the first to develop the screening, characterization, and production of
bacteriophage viruses, intended to treat bacterial infections, including those resistant to antibiotics
(AMR). This new therapeutic approach has been submitted to regulatory agencies in several countries,
while developing original preclinical, clinical and bioproduction evaluation methods. The aim is to
register it in the European Pharmacopoeia. These treatments now make it possible to treat patients who
have failed antibiotic treatments.
The study and evaluation of anti-infectious diagnostics (antibiograms, phagograms, biofilm, Sars-Cov-2 serological detection test, etc.) are also part of BioMaje skills.